CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Palatin Technologies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Palatin Technologies Inc
4-B Cedar Brook Drive
Cedar Brook Corporate Center
Phone: (609) 495-2200p:609 495-2200 CRANBURY, NJ  08512  United States Ticker: PTNPTN
Business Summary
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Its product development activities focus primarily on the use of MC4R agonists for treatment of obesity. It develops MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. It also develops MC1R agonist products to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20256/30/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board John K.Prendergast 71 1/1/2014 8/1/1996
President, Chief Executive Officer, Director CarlSpana 62 6/14/2000 6/25/1996
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary Stephen T.Wills 69 6/1/2011 11/1/1997
4 additional Officers and Directors records available in full report.

Business Names
Business Name
PTN
PTNT
PTNTD
RhoMed Incorporated

General Information
Number of Employees: 29 (As of 9/19/2025)
Outstanding Shares: 1,772,199 (As of 2/13/2026)
Shareholders: 50
Stock Exchange: ASE
Federal Tax Id: 954078884
Fax Number: (609) 495-2202
Email Address: info@palatin.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 11, 2026